Y-Intercept (HK)
CRVS icon

Y-Intercept (HK)’s Corvus Pharmaceuticals CRVS Stock Holding History

Y-Intercept (HK)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-43,769
Closed -$654K – 1662
2026
Q2 		$654K Buy
+43,769
New +$607K 0.01% 1224

Other funds holding CRVS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Y-Intercept (HK)'s CRVS Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Corvus Pharmaceuticals (CRVS) in Q3 2026, closing a stake of 43,769 shares — an estimated $654K sold.

Y-Intercept (HK) first reported a position in CRVS in Q2 2026 and held it in 1 quarter. The position peaked at $654K in Q2 2026. 75 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Corvus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 43,769 Corvus Pharmaceuticals shares in Q3 2026, an estimated $654K.
  • Y-Intercept (HK) first reported a position in Corvus Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Y-Intercept (HK)'s Corvus Pharmaceuticals position peaked at $654K in Q2 2026.
  • 75 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.